natgillin/translations-raw huggingface dataset:
Any other number of folds may be further introduced into the napkin 100 so that the folded napkin is of a required size. The adhesive of the first and second adhesive portions 102, 104 is to be of a type that will allow the first and second adhesive portions 102, 104 to separate so that after unfolding a napkin 100 which was previously folded like in figure 2, the napkin may to be subsequently adhered to a person, a person's clothing, or any other object. 
Metoda primjene adheziva na ubrus (100), metoda obuhvaća korake: preklapanja ubrusa duž prvog nabora; nanošenja prvog i drugog prijanjajućeg dijela (102, 104) na prvu površinu (106) ubrusa; i preklapanje navedenog ubrusa duž drugog nabora tako da navedeni prvi i drugi prijanjajući dijelovi međusobno naliježu; pri čemu je navedeni adheziv takve vrste koja će omogućiti navedenim prvim i drugim prianjajućim dijelovima razdvajanje i omogućiti navedenom ubrusu prianjanje na objekt.
is independently selected from: halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy; alternatively, R6 and R7, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising carbon atoms and 1-3 heteroatoms selected from N, NRe, O, and S; wherein said heterocycle is substituted with 0-2 Rg; 
R' je nezavisno odabrano od: halogen, C1.4 alkil, C,4 alkoksi, C,4 haloalkil, i Ci.4 haloalkoksi; alternativno, R* i R", zajedno sa ugljikovim atomima za koje su oni vezani, se kombiniraju da formiraju 5- do 6-očlani karbociklični prsten ili 5- do 6-očlani heterociklični prsten koji sadrži ugljikove atome i 1-3 heteroatoma odabrana od N, NR", O, i S; gdje spomenuti heterociklus je supstituiran sa 0-2 R#;
Such inks are formulated on the basis of optically variable pigment (OVP), a preferred type of OVP being the flaky thin-film optical interference device described in US 4,705,300; US 4,705,356; US 4,721,217; US 4,779,898; US 4,930,866; US 5,084,351 and in related disclosures. 
Takve se tinte proizvode na temelju optički varijabilnog pigmenta (OVP), a poželjan oblik OVP-a čini pahuljasto tankoslojno sredstvo za optičku interferenciju opisano u US 4,705,300; US 4,705,356; US 4,721,217; US 4,779,898; US 4,930,866; US 5,084,351 i povezanim objavama.
an inverse quantizer that performs inverse-quantization and inverse-transformation on the quantized transformation coefficients of the at least one transformation unit to obtain residuals; and 
Uređaj za kodiranje slike, te uređaj sadrži: memoriju koja pohranjuje tok bitova; i najmanje jedan procesor konfiguriran za:
Use according to any of claims 15 or 16, characterised in that the pain is selected from the group formed by cephalea, odontalgia, otalgia, dysmenorrhea, migraine, muscular pain, articular pain, osteoarthritis, neuropathic pain, post-traumatic pain, post-surgical pain and oncological pain. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 14 ili 15, naznačena time što se bol bira iz skupine koju čine glavobolja, zubobolja, uhobolja, dismenoreja, migrena, bol u mišićima, bol u zglobovima, osteoartritis, neuropatska bol, posttraumatska bol, postoperativna bol i onkološka bol.
A method for making a humanized mouse, comprising replacing all mouse exons encoding ectodomain sequences of mouse IL-6Ra with a human genomic fragment encoding human IL-6Ra ectodomain to form a humanized IL-6Ra gene, wherein the humanized IL-6Ra gene is under control of endogenous mouse regulatory elements. 
Postupak za stvaranje humaniziranog miša, naznačen time da sadrži zamjenu svih mišjih eksona koji kodiraju sekvence ektodomene za mišji IL-6Ra sa ljudskim genomskim fragmentom koji kodira ljudsku ektodomenu IL-6Ra da se dobije humanizirani IL-6Ra gen, pri čemu je humanizirani IL-6Ra gen pod kontrolom regulacijskih elemenata endogenog miša.
or a stereoisomer and/or a pharmaceutically acceptable salt thereof. 
o)0H O ili njegova farmaceutski prihvatljiva sol, stereoizomer, 1/ili N-oksid.
The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in therapy. The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in treating autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. 
Upotreba spoja u skladu s patentnim zahtjevom 1, ili njegove farmaceutski prihvatljive soli, naznačena time što je spoj namijenjen proizvodnji medikamenta namijenjenog upotrebi u liječenju jednog ili više bolesnih stanja, koja se bira iz skupine koju čine: autoimuni poremećaji, upalne bolesti, kardiovaskularne bolesti, neurodegenerativne bolesti, alergija, astma, pankreatitis, insuficijencija više organa, bolesti bubrega, agregacija trombocita, rak, pokretljivost sperme, odbacivanje transplantacije, odbacivanje presatka i ozljede pluća, kod ljudi.
Xaa2 is Trp or an analog of Trp, wherein the analog of Trp has increased hydrophobic character as compared with Trp, with the proviso that, if Xaa3 is Trp, Xaa2 is an analog of Trp comprising 5-fluoro- or 6-fluoro-l-tryptophan, or a lower alkoxy or lower alkyl substituent at the 1 or 5 position of tryptophan, or a lower alkanoyl substituent at the 1 position of tryptophan; Xaa3 is Trp or an analog of Trp comprising a chemical modification to its indole ring wherein the chemical modification increases the hydrogen bond potential of the indole ring; 
Xaa2 je Trp ili njegov analog, gdje analog od Trp ima pojačan hidrofobni karakter u odnosu na Trp i odabire se između halogeniranog triptofana, 5-metoksitriptofana, 5-metiltriptofan i 1-metiltriptofana, uz uvjet da ako Xaa3 je Trp, Xaa2 je analog od Trp; Xaa3 je Trp ili njegov analog gdje je vodik u indolu zamijenjen atomom fluora čime je pojačan potencijal vodikove veze indolnog prstena;
Tc is the condensation temperature, and Tm is the melting temperature of the metal to be precipitated, creating the conditions for the occurrence of a significant number of crystal nucleation centres. 
Tc < Tm, gdje Tc je temperatura kondenzacije, i Tm je temperatura topljenja metala koji se taloži, stvarajući uvjete za pojavu značajnog broja centara nukleacije kristala.
A prestretched film according to claim 3, wherein the film further comprises low density polyethylene (LDPE). 
Prethodno rastegnuta folija prema zahtjevu 1, gdje folija dalje sadrži polietilen niske gustoće (LDPE).
reacting the intermediate product of a) with a compound of formula (1): or a pharmaceutically acceptable salt thereof, under suitable conditions to form the compound of formula (4), or a pharmaceutically acceptable salt thereof. 
N H ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (4), ili njegove farmaceutski prihvatljive soli.
a frame composed of at least two posts (15) connected by a top crossbeam (16) placed transversely inside said stall; 
– okvir kojeg čine najmanje dva stupa (15), koje povezuje vršna prečka (16), smještena poprečno unutar navedene kabine;
In still another embodiment, the invention provides soft chewable compositions comprising Compound A in combination with ivermectin, milbemycin oxime or moxidectin, or a combination thereof. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 26, naznačen time, da makrociklički lakton je ivermektin, milbemektin, milbemicin oksim ili moksidektin, ili njihova kombinacija.
The controlled release composition according to embodiment 30 for administration twice daily. 
Sastav za kontrolirano otpuštanje u skladu s patentnim zahtjevom 1 za primjenu dvaput dnevno.
Alternatively, the compound may have the formula: 
Spoj, naznačen time, da ima formulu:
and R9 are independently selected from the group consisting of H, R, OH, OR, SH, SR, NH2, NHR, NRR′, nitro, Me3Sn and halo; wherein R and R′ are independently selected from the group consisting of optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; 
R* i R? su neovisno odabrane od sljedećih: H, R, OH, OR, SH, SR, NH», NHR, NRR(, nitro, Me3Sn i halo; gdjesu Ri R' neovisno odabrane od opcijski supstituiranih skupina: C1.,2 alkil, C3.29 heterociklil i C5.29 aril;
The method of claim 24 wherein the condition is ischemia/reperfusion injury. 
Spoj patentnog zahtjeva 10 gdje je stanje ishemija/reperfuziona povreda.
At this point, the devices 35 are operated to free the plate 30 from the plate 31; continuing the movement of the rods 32, the container 10 with the handle 11 perfectly assembled, can be finally disengaged from the demolding ring 26, and expelled from the mold. 
- < odvajanje navedenih dijelova za modeliranje (40, 41) od prstenastog elementa (15) i od zatika (14), te naknadnog završavanja vađenja iz kalupa proizvoda, sa navedenim prvim i drugim dijelovima kalupa (10, 11) u njihovom sklopljenom stanju.
A compound, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure of Formula I: 
Spoj, ili farmaceutski prihvatljiva sol spoja, naznačen time što spoj ima strukturu Formulo 1:
The time period is one minute, for example. According to a very preferred embodiment, the diaper accessory comprises a communication unit for communicating with mobile electronic devices. 
Postupak prema jednom od zahtjeva 1 do 6, kod kojeg modul pelene (2) sadrži komunikacijsku jedinicu (7) za komunikaciju sa mobilnim elektroničkim uređajima (8).
Microwave heated experiments were performed with a Personal Chemistry Emrys Synthesiser or a Personal Chemistry Emrys Optimiser. 
Ispitivanje gdje se radi zagrijavanje mikrovalovima izvodi se s Personal Chemistry Emrys Synthesiser ili s Personal Chemistry Emrys Optimiser.
The compounds were added in vitro to determine their inhibitory activity over the capacity of oxidation of plasma induced by Cu2+ (CuSO4). 
Spojevi su dodani in vitro za određivanje njihovog inhibicijskog djelovanja u sposobnosti oksidacije plazme izazvane s Cu"* (CuSO,).
In order to solve the sunstruck problem it has been proposed to reduce the amount of riboflavin in the beer (“Sunstruck Flavour Formation in Beer” by Sakuma et al. 
Da bi se riješio problem užeglosti predloženo je da se smanji količina riboflavina u pivu ("Sunstruck Flavour Formation in Beer" od Sakuma i sur.
a phase a) for growth of said microorganism in the presence of at least one carbonaceous growth substrate in a closed reactor, said growth phase being carried out with a concentration of carbonaceous growth substrate in the range 10 to 90 g/L; 
* faza a) za rast navedenog mikroorganizma u prisutnosti najmanje jednog ugljičnog supstrata za rast u zatvorenom reaktoru, pri čemu se navedena faza rasta provodi s koncentracijom ugljičnog supstrata za rast u rasponu 10 do 90 g/L;
Figure 4 depicts the method of synthesis for 31-O-(D-Fructosylcarbonyl)rapamycin. 
Slika 4 prikazuje postupak sinteze 31-O-(D-fruktozilkarbonil)rapamicina.
A pharmaceutical combination of Claim 25 wherein the hypolipidemic agent is an ATP citrate lyase inhibitor. 
Farmaceutski sastav Zahtjeva 25, naznačen time, da je hipolipidemijsko sredstvo inhibitor ATP citrat liaze.
A process according to any one of claims 6 to 8 wherein the solvent system comprises one or more water-miscible solvents and water. 
Postupak prema bilo kojem od patentnih zahtjeva 6 do 8, naznačen time da sustav otapala sadrži jedno ili višo otapala mješljiva s vodom i vodu.
each R5 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; 
svako Rd nezavisno je R2d, izborno supstituirani alifatik, ili izborno supstituirani aril, heteroaril ili heterociklil grupa;
A packaging method according to claim 1, wherein the polylaminate that seals the top of the cup-shaped body in step (b1.5) comprises a first layer made of polyethylene terephthalate, a second layer made of aluminum and a third layer made of polypropylene. 
Postupak pakiranja u skladu s patentnim zahtjevom 1, naznačen time, da polilaminat koji brtvi vrh kućišta u obliku čaše u koraku (b1.5) sadržava prvi sloj od polietilen tereftalata, drugi sloj od aluminija i treći sloj od polipropilena.
expression of at least one neural-specific antigen selected from the group consisting of neural-specific microtubule associated protein 2 (Map2), neural cell adhesion molecule (NCAM), and a marker for a neurotransmitter upon neuronal differentiation; 
ekspresiju najmanje jednog neuronski-specifičnog antigena koji je izabran iz grupe koja obuhvaća neuronski-specifični tubulin, protein 2 koji se veže za mikrotubule, NCAM, i marker za neurotransmiter;
collecting water at a condenser; heating the water; and using the heated water for the processing of the first energy source and the biomass fuel source. 
Postupak sukladno zahtjevu 1, koji dalje sadrži: sakupljanje vode kod kondenzatora (142); zagrijavanje vode; i upotrebu zagrijane vode za preradu prvog izvora energije i biomase kao izvora goriva.
Because the fuel element is relatively short, the hot, burning fire cone is always close to the aerosol generating body, which maximizes heat transfer to the aerosol generating means, and resultant production of aerosol, especially when a heat conducting member is used. 
Zato što je gorivi element 10 poželjno relativno kratak, vruć, gorivi plameni konus je uvijek blizu tijela za generiranje aerosola, što maksimira prijenos topline u sredstvo za generiranje aerosola, pa nastaje proizvodnja aerosola, naročito kada se koristi poželjan član za provođenje topline.
is Lys, wherein the —NH2 side chain group is functionalized by one of the groups selected from the group consisting of (S)-4-Carboxy-4-hexadecanoylamino-butyryl-, and (S)-4-Carboxy-4-octadecanoylamino-butyryl-. 
predstavlja Lys, pri čemu je -NH2 skupina bočnog lanca funkcionalizirana s jednom od skupina koje se biraju od (S)-4-karboksi-4-heksadekanoilamino-butiril-, (S)-4-karboksi-4-oktadekanoilamino-butiril-.
The method according to claim 1, wherein step a) comprises adding a metal chelating agent. The method according to claim 4, wherein the metal chelating agent is EDTA, EGTA, or citric acid. 
Postupak in vitro prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da korak a) obuhvaća dodavanje kelatnog sredstva za metal, kao što je EDTA, EGTA ili limunska kiselina.
The immunogenic composition of any one of claims 1-2 wherein the second bacterial toxoid is selected from the group consisting of tetanus toxoid, diphtheria toxoid, CRM197, pertussis toxoid, a bacterial cytolysin and pneumolysin. The immunogenic composition of any one of claims 1-3 further comprising conjugates of S. pneumoniae capsular saccharides 4, 6B, 9V, 14, 18C, 23F, 1, 5 and 7F. The immunogenic composition of claims 1-4 further comprising a conjugate of S. pneumoniae capsular saccharide 22F. 
Imunogeni pripravak, naznačen time što sadrži konjugate saharida iz kapsule bakterije S. pneumonijae iz serotipova 19A i 19F, gdje je 19A konjugiran s prvim bakterijskim toksoidom, koji je pneumolizin, difterijski toksoid ili CRM197, a 19F je konjugiran s drugim bakterijskim toksoidom, koji je difterijski toksoid ili CRM197, te što dodatno sadrži konjugate saharida 4, 6B, 9V, 14, 18C, 23F, 1, 5 i 7F iz kapsule bakterije S. pneumonijae, gdje je prosječna veličina saharida 19A između 110 i 700 kDa. Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži konjugat saharida 22F iz kapsule bakterije S. pneumonijae.
In one variation, the articles of manufacture further comprise packaging materials such as a container for housing the multiple doses of the pharmaceutical composition and or a label indicating one or more members of the group consisting of a disease state for which the compound is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. 
Proizvodni artikl prema patentnom zahtjevu 41, naznačen time što kontejner sadrži etiketu koja ukazuje na jednog ili više članova grupc koju čine stanje bolcsti za koju sc spoj primjenjuje, informacije o čuvanju, informacije o doziranju i/ili uputstva vezana za to kako primjenjivati kompoziciju.
A method of controlling undesired vegetation, which comprises applying a synergistic herbicidal mixture as claimed in claims 1 or 2 before, during and/or after the emergence of undesired plants simultaneously or in succession. 
Postupak kontrole neželjene vegetacije, a koji obuhvaća primjenu sinergijske herbicidne smjese prema bilo kojem od prethodnih zahtjeva 1 do 2, prije, tijekom i/ili nakon pojave neželjenih biljaka istodobno ili uzastopno.
It is clear that insertions and deletions of amino acids may also be made in the above-defined sequences without altering their function, particularly if the insertions or deletions only involve a few amino acids, e.g., under thirty, and preferably under ten, and do not remove or displace amino acids which are critical to a functional conformation, e.g., cysteine residues. 
Jasno je da insercije i delecije amino kiselina također se mogu uvoditi u gore definirane sekvence bez da se mijenja funkcija posebice ukoliko insercije ili delecije uključuju nekoliko amino kiselina tj. ispod trideset, a poželjno ispod deset te da se pri tome ne miče ili mijenja položaj onih amino kiselina koje su presudne za funkcijsku konformaciju kao primjerice ostaci cisteina.
The compound, salt, or composition of claim 17 for use in combination with an anti-cancer vaccine, an anti-viral agent, a chemotherapeutic, an immunosuppressant, radiation, an anti-tumor vaccine, an anti-viral vaccine, cytokine therapy, or a tyrosine kinase inhibitor. 
Spoj, sol ili sastav prema patentnom zahtjevu 32, naznačen time da se koristi u kombinaciji s cjepivom protiv raka, protuvirusnim sredstvom, kemoterapeutikom, imunosupresantom, zračenjem, cjepivom protiv tumora, cjepivom protiv virusa, terapijom citokinima ili inhibitorom tirozin kinaze.
Cumulative Productivity and Glucose Consumption Rate During Runs with Non-Recycled or with Recycled Fibra-Cel® Disks 
Ukupna produktivnost 1 stopa trošenja glukoze tijekom rundi s recikliranim ili ne-recikliranim diskovima Fibra-Cel"
(iii)a synthetic material layer applied over and to the adhesive layer (ii); 
(1li) sloj sintetskog materijala, kojeg se primjenjuje preko i na sloj ljepila (fi);
A toilet bowl unit according to claim 1, wherein the peripheral water channel is located radially outwards of an outer toilet bowl surface of the toilet bowl. 
Jedinica toaletne školjke prema patentnom zahtjevu 1, naznačena time što je obodni kanal za vodu (210) smješten radijalno izvan vanjske površine toaletne školjke (106) toaletne školjke (101).
The reaction mixture is heated at 90° C for one hour, cooled to room temperature and a solution of 4-chloro-but-2-yn-l-ol (4.80 g, 0.045 mole) in N,N-dimethylformamide (10 mL) is added and stirred for 2 hours at room temperature. 
Reakcijsku smjesu grije se 1 sat na 90 "C, ohladi do sobne temperature, doda se otopina 4-klorbut-2-in-1-ola (4,80 g, 0,045 mol) u N,N-dimetilformamidu (10 ml), te miješa 2 sata na sobnoj temperaturi.
forming a derivative (such as an ester) with an optically pure chiral derivatising agent (e.g. esterifying agent), separating the resulting epimers (e.g. by chromatography) and then converting the derivative to the dihydrotetrabenazine. 
(ill) formiranjem derivata (poput estera) s optički čistim sredstvom za formiraje derivata (na primjer sa sredstvom za esterifikaciju), odijeljivanjem rezultirajućih epimera (na primjer kromatografijom) i zatim prevođenjem derivata u dihidrotetrabenazin.
The present invention further relates to a method for treating neurodegenerative diseases caused by abnormal activity of GSK3B and of the aforementioned diseases which comprises administering to a mammalian organism in need thereof an effective amount of a compound of the formula (I). 
Ovaj izum također se odnosi na postupak liječenja neurodegenerativnih bolesti uzrokovanih abnormalnom aktivnošću GSK3f i gore navedenih bolesti, koji se sastoji u primjeni na organizmu sisavca kojem je to potrebno djelotvorne količine spoja formule (1).
Use according to claim 1 wherein the compound of formula (Ia) or (Ib) is a compound having the following formula a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N -oxide form thereof. 
Uporaba prema zahtjevu 1 naznačena time da spoj sa formulom (Ia) ili (Ib) je spoj koji ima slijedeću formulu [image] [image] njegova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njegov stereokemijski izomerni oblik, njegov tautomerni oblik ili njegov N-oksid.
The average value as calculated in this,phase is stored inside the unit 50 and assumes the meaning of zero-reference value for the A/D converter. 
Srednja vrijednost izračunata u ovoj fazi je spremljena u jedinicu 50 i predstavlja nultu-referencu za A/D pretvarač.
It should be noted that hydrogenation of the N,N-dibenzyl starting material in Example 8 produced the monobenzyl product which was in turn used as the starting material in Example 9. 
Treba se naglasiti da je hidrogenizacija N,N-dibenzil polaznog materijala u Primjeru 8 proizvela monobenzil proizvod koji je onda korišten kao polazni materijal u Primjeru 9.
The nail is 1000 times more permeable to water than the skin, and consequently the nail structure reacts to prolonged or repeated contact with water. 
Nokat je 1000 puta propusniji za vodu nego koža, i posljedično struktura nokta reagira na produljeni ili ponavljajući kontakt s vodom.
In formulation with polyester approximately 50% of the RME remain in the coating at this temperature. 
U formulaciji s poliesterom pri toj temperaturi u prevlaci zaostaje približno 50% RME-a.
The same reference numerals will generally be used for the same parts as those in FIGS. 1-6 b, even though small differences may occur. 
Isti odnosni brojevi će se općenito koristiti za iste dijelove kao i na slikama 1- 6b, čak ako bi to moglo uzrokovati male razlike.
The vaccine of claim 3, wherein the carrier protein is a bacterial toxoid or derivative, Pseudomonas exotoxin, KLH or a virus-like particle. 
Cjepivo u skladu s patentnim zahtjevom 2, naznačeno time što je proteinski nosač bakterijski toksoid ili njegov derivat, egzotoksin iz bakterije Pseudomonas, KLH ili virusu slična čestica.
caspofungin dipropionate, in a concentration corresponding to 0.1 mg/ml to 500 mg/ml, e.g. of about 10 mg/ml to about 200 mg/ml, preferably 20 mg/ml to 60 mg/ml, more preferably about 22 mg/ml to about 45 mg/ml, most preferably of about 25 mg/ml, of about 30.6 mg/ml or of 42 mg/ml of caspofungin calculated as caspofungin base, and 
Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da obuhvaća 0,1 mg/ml do 500 mg/ml, poželjno 20 mg/ml do 60 mg/ml kaspofungina, računajući kao kaspofungin bazu, 10 mg/ml do 200 mg/ml, poželjno 40 mg/ml do 60 mg/ml pomoćnog sredstva, koje je punilo za povećanje mase, poželjno mješavina šećernih punila za povećanje mase, učinkovitog za tvorbu liofiliziranog kolača, i vodu.
A prosthetic heart valve comprising a tubular frame made of a plastically deformable material selected from group comprising stainless steel and cobalt-chromium alloy, the prosthetic heart valve having a radially collapsed state and radially expanded state, the frame comprising: 
uređaj za dopremu koji sadrži produženu osovinu (180) koja ima balon na napuhavanje (182), i protetski aortni srčani ventil koji ima okvir (12) koji ima radijalno skupljeno i radijalno prošireno stanje, pri čemu okvir (12) sadrži:
wherein the wavy line indicates the attachment site to the linker L. The method of claim 4, wherein D is maytansinoid. 
[image] gdje valovite linije označavaju mjesto priključenja na poveznicu L; D je MMAF, koja ima strukturu:
The process according to claims 1, 2 or 3, wherein P1 is acetyl; P4 is a tBu, P6 is hydrogen or tBut, and P8 is Boc. 
Postupak u skladu s patentnim zahtjevima 1, 2 ili 3, pri čemu je P1 acetil; P4 je tBut, a P8 je Boc.
is C1-C18 alkyl; or a pharmaceutically acceptable salt, hydrate, solvate or complex thereof. 
R* je C;-C,g alkil; ili njegova farmaceutski prihvatljiva sol, hidrat, otopina ili kompleks.